GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2018-10-26| R&D

Update on Tuberculosis containment using vaccine – Taming the disease

by GeneOnline
Share To

By Ajay V. Patil

The epidemiological menace of Tuberculosis (TB)

Tuberculosis now surpasses HIV and Malaria infections worldwide with 10.4 million new cases and 1.7 million deaths annually. This also includes 0.4 million deaths in people with HIV infection (1). In such dire straits, WHO developed ‘End TB Strategy’ with an ambitious goal of reducing the 90% incidence of tuberculosis disease by 2035. But on the ground, there is only reduction in TB mortality rate (decline by 30% since year 2000) and slight decrease in incidence (1-2% per year). Incidence of drug-resistant disease is also rising to add the burden.

Challenges in TB vaccine development for protection against disease

In most infectious diseases, vaccines are considered as most effective and economical interventions for protection against the disease. TB disease is historically known for posing difficult challenge in using vaccination to contain disease development. Mainly, detailed knowledge of immunologic mechanisms for protection against tuberculosis is vital, given that the disease develops in only 5 to 10% of patients infected with M. tuberculosis. However, immunodeficiency increases this risk to approximately 8% per year. Other important argument is the conflicting reports of British Medical Research Council trial with BCG vaccine in adolescents (87% protective against disease and 74% protective at 20 years) and the largest 15 years long BCG vaccine trial, with 260,000 people in India (no protection in any age group). Prior exposure to M. tuberculosis or nontuberculous mycobacteria in Indian population, was reported to cause the interference in the detection of any additional protection provided by the vaccine in this case. There were more disappointing attempts in this quest for better vaccination against TB.

M72/AS01E vaccine Phase IIb results – new hope in the pipeline

However recently published study by Van Der Meeren and group showed significant efficacy in the prevention of clinical tuberculosis by a subunit vaccine, M72/AS01E, among people already infected with M. tuberculosis. This vaccine has two M. tuberculosis proteins with AS01E adjuvant. The primary end point was, ‘preventing active pulmonary tuberculosis in adults’ who had received the BCG vaccine as children in almost all the cases. The trial was conducted in about 3500 adults in 11 centers in South Africa, Kenya, and Zambia. The overall vaccine efficacy was 54% (achieved proof of principle). Interestingly, protection was greater in 25 years of age or younger participants than older participants. Also, men were found to benefit more than women. The role of adjuvant AS01E is assumed to be critical in this trial (same adjuvant used in malaria vaccines).

Envisioning future – research and access

Detailed understanding of immunologic and expression profile differences between recipients who were protected and those who were not can plausibly validate this vaccine as ‘proof of concept’. ‘Durability of protection’ and ‘need for revaccination’ are also important determining factors in this case. Further, phase III trial in multiple geographic populations will be an important cornerstone for such vaccine considering the epidemiology of infection. Once validated through the scientific and clinical timelines there are additional challenges to facilitate the affordable access worldwide (considering 95% incidence in low-and-middle-income countries).

References

  1. https://www.nejm.org/doi/full/10.1056/NEJMe1812483?query=featured_secondary
  2. https://www.nejm.org/doi/10.1056/NEJMoa1803484

 

DiagSummitAsia2018-Web-Banner

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Roche’s STI Test Clears FDA Potentially Becoming A Game-Changer for Fast, Accurate Diagnosis
2025-01-23
Trump’s Move to Ditch the WHO Again: Day 1 Sees a Slew of Executive Orders Signed Off
2025-01-21
Can We Beat Cervical Cancer for Good? The Secret Weapon Lies on HPV Vaccines and Early Screenings
2025-01-06
LATEST
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top